ªÑªF·|­«ÂI
·|­û:fun 10138468 µoªí®É¶¡:2014/6/30 ¤U¤È 10:40:45
ªÑªF·|­«ÂI1.Anti-Cemx ¦~©³°e¥óFDA,¥Ó½Ð¶i¤JIND(·sÃÄÁ{§É¸ÕÅç¡^¡C2.Anti-Cemx °ê»Ú±ÂÅvª÷¦p´CÅé©Ò¨¥¤W¬Ý5»õ¬ü¤¸¤w¤W¡C3.»PGSKñ«O±K¨ó©w,¤´¦b¶i¦æ¤¤¡C4.Xoliar³J¥Õ½è¬Û¦üÃÄ»P¤j³°±á¬P¶°¹Î¹w­p¦~©³Äâ¤â¤j¤¤µØ±ÂÅv¬u²±,°ª¼h¹ï©ó¤½¥q·sÃÄ«H¤ßº¡º¡³á¡I

¬u²±¦~³ø´¦ÅS,2012¦~¥þ²y«e10¤jÃÄ«~,²Ä¤@¦WGSK,¨ä®ð³ÝÃĦ~¾P°âÃB¬°89»õ¬ü¤¸¡C²Ä¤G¦W¬°Abbot,¨äÃþ­··ÃÃö¸`ª¢ÃĦ~¾P°âÃB¬°85»õ¬ü¤¸,³o¨â¶µÃĬҬ°¬u²±¥D¤O²£«~,¥]¬AAnti-Cemx, Xolair, Anti-IL6. ©Ò¥H¤@°_´Á«Ý¦~©³¨Î­µ¡C

·|­û:¥²³Ó10142431µoªí®É¶¡:2017/6/22 ¤U¤È 12:52:05²Ä518½g¦^À³
§Ú¸ÕµÛ§äRocheªºQuilizumab°µ§¹¤G´Á¤£°µ¤Fªº¸ê®Æ

³o­ÓÀ³¸Ó¬O

adisinsight.springer.com/drugs/800032472

ª¬ºA¬ODiscontinued

­Y¦³¿ù»~½Ð«ü¥¿

·|­û:¥²³Ó10142431µoªí®É¶¡:2017/6/22 ¤U¤È 12:17:03²Ä517½g¦^À³
§Ú¤]¬OÃú·Ù·Ù

¤£¹L¤@¦~¾P°âª÷ÃB°ª¹F300»õ¬ü¤¸¥H¤Wµ¥©ó9000»õ¥x¹ô

¬u²±ªÑ¥»¤~30»õ¥x¹ô¡A¤@¦~eps¤£´N§Ö3000¤¸

±N¨ÓªÑ»ùÀ³¬O¦b30000¤¸³£ÁÙ¶û¤Ó§C

¦ý¥H²{¦bªÑ»ù­nº¦5­¿§Ú¤~¯à¸Ñ®M

¥u¨õ·L¦a½Ð¨DÅý§Ú¸Ñ®M§a

³Ñ¤Uªº§ÚÄ@·NÅý§O¤H¥hÁÈ

·|­û:¾ÖÅ@ªÌ10140685µoªí®É¶¡:2017/6/22 ¤W¤È 11:11:06²Ä516½g¦^À³
fun¤j¼gªº:

2.FB704(anti-IL6):

¥Ø¼Ð±ÂÅv¤jÃļt¦@¦P¬ãµo¡A¤w©M¦h®aÃļtñ©wCDA,¹w­p¤µ¦~¦~©³¥Ó½Ð¬ü°êIND¡C§Ú»P¬ãµoªø³£¤£¬ù¦Ó¦Pªº»{¬°FB825¬O¬u²±ªºª÷Âû¥À¡C¤@¦~¾P°âª÷ÃB°ª¹F300»õ¬ü¤¸¥H¤W¡C¦pªG¦¨¥\±ÂÅv±N¬O¦¬¯q±NÃø¥H¦ô­p¡C

cscs¤j¼gªº:

RocheªºQuilizumab°µ§¹¤G´Á¤£°µ¤F

¦Ó¤½¥q²{¦b¤~»¡FB825¤G´ÁÁ{§É¤~­n¶}©l

¤W­z¬Ý¨Ó,,¬O¤£¬O¬Ý¨ìù¤óÃļtªºª¬ªp,©ì©µ2´ÁÁ{§É,¬Æ¦Ü­n©ñ±ó,

¦ý¤S¦bªÑªF·|¤W»¡¬Ý¦n

¥²³Ó¤j:§A»{¬°·|¤£·|¤S¬O¤@³õ¤jÄF§½¤F.¦]¬°§Ú­Ì¨â­Ó³£³QÄF©È¤F...«¢«¢«¢«¢

·|­û:cscs10144679µoªí®É¶¡:2017/6/20 ¤U¤È 05:52:26²Ä515½g¦^À³
RocheªºQuilizumab°µ§¹¤G´Á¤£°µ¤F¡AFB825°w¹ï¦P­Ótarget¡A±¡ªp¤]¤£·|¤Ó¼ÖÆ[¡A

·íµM¤]­nµ¥¤G´Á°µ§¹¤~ª¾¹D¦³¨S¦³®Ä¡A¥ú¥ÎFB825¡A´î¤Ö¦å²GIGEªº¿@«×«á¡A¹ê»Ú¯gª¬¤]¤£¤@©w¦³´î½w¡A

RocheªºQuilizumab´N¬O³o¼Ëªºµ²ªG¡C

FB825¸òRocheªºQuilizumab§¹¥þ¤£¦PªF¦è¡A¥u¬O·|»{¦P­Ó¼Ðªº¡A

¦U¦Ûµo®i¡A¤£¬OROCHE°µ§¹µ¹¥xÆW°µ¤G´Á¡C

¤T­Ó¤ëµ¹ÃĤ@¦¸¤£¬O¤°»òÀu¶Õ¡Atarget¤£¦P¡A¥Îªº¾¯¶q¤£¦P¡A

Anti-IL6¤]¨S¤°»ò¥Î¡A³o¤@­ÓÄvª§ªÌ¦³¦h¤Ö¡A¬u²±¦³¤°»ò±j¶µ¯à¥´±oĹ?

§O¹ïFB¦³¤Ó¤jªº´Á±æ¤F

·|­û:¾ÖÅ@ªÌ10140685µoªí®É¶¡:2017/6/20 ¤W¤È 11:10:11²Ä514½g¦^À³
¯uªº¦³ªº©ì¤F

¦Ó¥B2´ÁÁÙ¨S¹L

¤WÂd¤§¤é¤]¬O»»»»µL´Á

·|­û:¥²³Ó10142431µoªí®É¶¡:2017/6/20 ¤W¤È 10:24:07²Ä513½g¦^À³
²Ä¤G´Á¤À2a©M2b

­n±ÂÅv°_½X­n®³¥XÁ{§É¼Æ¾Úµ¹°ê»ÚÃļt¬Ý

§Ú¬Ý¦³ªº©ì¤F

·|­û:¾ÖÅ@ªÌ10140685µoªí®É¶¡:2017/6/20 ¤W¤È 09:08:17²Ä512½g¦^À³
¥²³Ó¤j:¤½¥q»¡Á{§É¥h¦~°e¥ó,¤µ¦~¤~¹L,§A»{¬°©O?¦³¥i¯à¶Ü?

·|­û:¥²³Ó10142431µoªí®É¶¡:2017/6/19 ¤U¤È 07:00:49²Ä511½g¦^À³
¾Ö¤j

¦­¤wº¡¨­¼u¤Õ¡A¶Ë²ª²Ö²Ö

³o¤@ºjÁÙ®¼±o¦í

·|­û:FLYER10133103µoªí®É¶¡:2017/6/19 ¤U¤È 02:07:33²Ä510½g¦^À³
«D±`ÁÂÁÂFun¤j±a¨ÓªÑªF·|²{³õªº°T®§...¡C
·|­û:¾ÖÅ@ªÌ10140685µoªí®É¶¡:2017/6/19 ¤W¤È 11:01:53²Ä509½g¦^À³
¨S¿ù,¤µ¦~¤~­n¶i¦æ2´ÁÁ{§É

¥²³Ó¤j,¬O¤£¬O¤S³Q¥´¤@ºj¤F

·|­û:¥²³Ó10142431µoªí®É¶¡:2017/6/17 ¤U¤È 11:01:07²Ä508½g¦^À³
·PÁÂfun¤j¼ö¤ßPO

½Ð±Ðfun¤jFB825TFDA2a­n²Ä¤G©u¶i¦æÁ{§É¹êÅç

¨º­ì¹w©w¤µ¦~¤E¤ë§¹¦¨TFDA2a¤£¬O©µ¦Ü©ú¦~²Ä¤G©u¤~§¹¦¨¶Ü

·|­û:fun10138468µoªí®É¶¡:2017/6/17 ¤U¤È 06:00:12²Ä507½g¦^À³
¥_¤W°Ñ¥[¬u²±ªÑªF·|¡A²{³õ¤j³¡¤À¬O¤½¥q¬£¤H­û¡A¦]¦¹¦¸¶i¦æÀ´¨Æ¿ï¾Ü®×¡A©Ò¥H¤½¥q¦ü¥G¤j°}¥M¦w±Æ«Ü¦h¤H­û°Ñ»P¡CªÑªF¤H¼Æ«o¹é¹é¥i¼Æ¡C·|¤¤§Ú»P¨ä¥LªÑªF´£°Ý¨Ç°ÝÃDÀò±o¬ãµoªø¸Ñµª¡C·|«á¬ãŪ§¹¬u²±¦~³ø¡A¤ß±o»P¬ãµoªø©Ò»¡ªø´Á¾Ö¦³¬u²±¡A±N·|¦³«D±`Âײ±ªG¹ê¤£¿Ñ¦Ó¦X¡C¬u²±»P¨ó©M¦X¨Ö«á¡Apipeline§ó¥[¦h¤¸¤Æ¥B·¥¨ãÄvª§©Ê¡C¨C­Ó²£«~³£¨ã¦³¿W¦û©Ê»P¹è¦û©Ê¥«³õ¡C¦Û©l¦Ü²×¬u²±¦b§Ú§ë¸ê²Õ¦X¸Ì»P¯E¹©¬O¨Ã¾r»ôÅXªº¡C¤½¥q¥Ø«eí©w¦P³¡±À®i·sÃĶ}µo»P¥Íª«¬Û¦üÃÄ¡C³sÄò5¦~ÂÍÁp¥þ²yÃÄ«~¾P°â²Ä£¸¦W¬Ò¬OÃþ­·ÀãÃö¸`ª¢(RA)ÃĪ«¡C2016¾P°âª÷ÃB¹F333.84»õ¬ü¤¸¡C¬u²±FB704A(anti-IL6)§Y¬O¥Î©óªvÀøRA¤Î§í¨î¸~½F¡C¾ã²zªÑªF·|­«ÂI¦p¤U:

1.FB825(Anti-C£`mX):

105¦~7¤ë»P¦h®aÃļtñ©w«O±K¨óijCDA ,¥Ø«e¤´¦b¨ó°Ó¤¤¡A°ê»Ú±ÂÅv¤@¯ë¨óij¥­§¡¯Ó®É1¦~¥b®É¶¡¡C¹w­p²Ä¤G©u¶i¦æ¥xÆWÁ{§É¤G´Á¹êÅç¡CFB825¾AÀ³¯g¬°²§¦ì©Ê¥Ö½§ª¢¡A¹w¦ô²§¦ì©Ê¥Ö½§ª¢ªº¥«³õ»ù­È¦Ü2022¦~¶È¦b¤E¤jÃÄ«~¥«³õ°ê«K±N¹F¨ì56»õ¬ü¤¸³W¼Ò¡CFDA¤µ¦~3¤ë©³®Ö­ãªº¥Íª«»s¾¯³æ®è§ÜÅéÃĪ«dupilumab¡A¥Î©óªvÀø¦¨¤H¤¤«×¨ì­««×ªº²§¦ì©Ê¥Ö½§ª¢¡Cdupilumab»Ý¤@©P¥´¤@°w©Î¨â©P¥´¤@°w¡A¦ÓFB825¬°3­Ó¤ëµ¹ÃĤ@¦¸¡A¦]¦¹§ó¬°Àu²§¡C2.FB704(anti-IL6):

¥Ø¼Ð±ÂÅv¤jÃļt¦@¦P¬ãµo¡A¤w©M¦h®aÃļtñ©wCDA,¹w­p¤µ¦~¦~©³¥Ó½Ð¬ü°êIND¡C§Ú»P¬ãµoªø³£¤£¬ù¦Ó¦Pªº»{¬°FB825¬O¬u²±ªºª÷Âû¥À¡C¤@¦~¾P°âª÷ÃB°ª¹F300»õ¬ü¤¸¥H¤W¡C¦pªG¦¨¥\±ÂÅv±N¬O¦¬¯q±NÃø¥H¦ô­p¡C

3.FB317(Omalizumab¥Íª«¬Û¦üÃÄ):

¤µ¦~±N©ó¤¤°ê¤j³°¶i¦æPhase 1, omalizumab 2015¦~¥þ²y¾P°âÃB23»õ¬ü¤¸¥H¤W¡C

4.FB121(Ibalizumab¥Íª«¬Û¦üÃÄ):

¥Ø«e«ùÄò¶i¦æ¥Í²£»s¦¨Àu¤Æ¡C

5.SNA01»PSNA02(§ÜPD1»P§ÜPDL-1§K¬ÌÀˬdÂI¾AÅé·sÃÄ):

aptamer¬O¤@ºØ¯à»P¯S©wªº¥Ø¼Ð¤À¤lµ² ¦Xªº¹è®Ö苷»Ä(Oligonucleotide)¡C ¥Ø«ePD-1 ¸~½F§ÜÅé¤@¦¸Àøµ{¬ù15 ¸U¬üª÷( ªñ500 ¸U·s¥x¹ô)¡A¦ýPD-1 §ÜÅ骺¦³®Ä²v¥u¦³25 ∼ 30¢H¡A¾AÅ骺§Q°ò¦b©ó¨ä¦¨¥»¥u¦³§ÜÅ骺1/10¡A2020 ¦~PD-1 §K¬ÌÀˬdÂI¹w¦ôªº¥«³õ±N±µªñ100 »õ¬üª÷¡CSNA01»PSNA02¦b¤p¹«¹êÅ礤¦³¥­§¡60%¸~½F§í¨îªí²{¡C

6.SNS01(tumor stem cell ):

°w¹ïªÍÀù·F²Ó­M§ÜÅé·sÃÄ¡A²{¦b¶i¤J §ÜÅé¿z¿ï¡C¥«³õ¾P°â«O¦u¦ô­p¨C¦~300»õ¬ü¤¸¡C

¤F¸Ñ§¹¬u²±©Ò¦³pipeline¶i«×¡A­Ó¤H»{¬°³o®a¤½¥q«D±`Àu²§¨C¤@¶µ²£«~³£·¥¨ãÄvª§©Ê¡A¥«³õ¿W¦û©Ê¡C¬Æ¦Ü¥Ø«e³Ì¨üÆf¥ØÀù¯g§K¬ÌÀøªk¡A¬u²±§ó¬O°Ñ»P¨ä¤¤¡C¬u²±¥¼¨Ó¤£¥i­­¶q¡A±N·|¦b°ê»Ú¤jÃļt¶¡¹ñÅSÀY¨¤¡C

§ë¸ê¦Û¦³°ª­·ÀI¡A½ÐÂÔ·V¦Û¦æµû¦ô¡A¶È¨Ñ°Ñ¦Ò¡C

·|­û:ªü·ç10144461µoªí®É¶¡:2017/6/15 ¤U¤È 11:59:28²Ä506½g¦^À³
¦³°Ñ¥[ªÑªF·|ªºª©¤Í¶Ü?

°£¤F¬u²±­ì¦³ªºFB825,FB704A, FB317, FB121¶i«×¤¶²Ð¥H¥~,¨Ö¤J¨ó©M·sÃÄ¥H«á,¨ä·sªºÃÄ«~¶}µo¼Ðªº&¶i«×¦³©Ò±Ô­z¶Ü?

ÁÙ¬O¨â®a¦X¨Ö«á,¦nÅ¥¥s°µ¿i¦X´Á,ÃøÅ¥¥s°µ¨¤¤O´Á,©Ò¥H¨ó©M·sÃĭ즳ªºÃÄ«~¶}µo´N¥ýÀÁ¤@Ãä¤F!

¬u²±·s¸ê¥»ÃB¬°30»õ¡A

¤¤¤Ñ(¤¤¤Ñ+¦X¤@)64170±i=21.39%¡B

´I¨¹½²®a68273±i= 22.76%¡B

Æp¥Û(Æp¥Û+ºë­^§ë¸ê(ªÑ)+Âײ±§ë¸ê(ªÑ))45777±i=15.26%,

¥x·s(¹Å¯E&Îë¥Ý) 5481±i(1.83%),

¥x¤j20649±i (=6.88%)

¥É¤s³Ð§ë3514±i (=1.17%)

¥H¤W¦X­p207864±i = 69.29%, ¤jªÑªF«ùªÑªñ¤C¦¨,µM«á©O!­ü!

·|­û:¥~¦æ¤H10135615µoªí®É¶¡:2017/6/15 ¤U¤È 08:07:39²Ä505½g¦^À³
¥x¤j20649±i ¥É¤s³Ð§ë3514±i
·|­û:¥²³Ó10142431µoªí®É¶¡:2017/6/15 ¤U¤È 07:19:42²Ä504½g¦^À³
¥x¤j«ù¦³¤£¤Ö§Þ³NªÑ¡A

¦ü¥G¨S¶i¤J¸³ºÊ®u¦¸¡A

¤£ª¾¦³µL³B²z¡H

·|­û:¥²³Ó10142431µoªí®É¶¡:2017/6/15 ¤U¤È 07:13:40²Ä503½g¦^À³
¤p½Þ¤jÀ³·|°Ñ¥[ªÑªF·|

µ¥¥LPO

·|­û:¥~¦æ¤H10135615µoªí®É¶¡:2017/6/15 ¤U¤È 06:44:33²Ä502½g¦^À³
·Pı¤£¤Ó¦n¬O¤jªÑªF¦³²§·N¥ç©Î¹B§@¯ó²v¡H
·|­û:FLYER10133103µoªí®É¶¡:2017/6/15 ¤U¤È 05:29:35²Ä501½g¦^À³
­è¬Ý¨ì¤½¥qµo¥¬­«¤j°T®§--³o¦¸¸³ºÊ§ï¿ï®×¡A¦³ªÑªF´£Ä³¼È½w´£«e§ï¿ï...¨S·Q¨ì³Ì«á¨MijÁÙ¬O¼È½w´£«e§ï¿ï...¤£ª¾­ì¦]¬°¦ó??
·|­û:¥~¦æ¤H10135615µoªí®É¶¡:2017/6/15 ¤U¤È 05:00:52²Ä500½g¦^À³
¦X¨Ö«á¸ê¥»ÃB¬°30»õ¡A¤¤¤Ñ21.39%¡B½²®a19.6%¡BÆp¥Û15.14%«e¤T¤jªÑªF¦X­p¦û56.13%Äw½X¶°¤¤¡A°ß¤@¯Ê¾Ñªº¬O¶È¦³½²®a¦³­Ó¤H«ùªÑ¡F¦]¦X¨ÖÃö«Y²o¯Aºî©Òµ|(¥i¯à¬O45%)°ÝÃDµu®É¶¡¤º³B©ó§C»ùÂà´«¥i¥H²z¸Ñ¡A¦ý¡A¤jµ§Âà´««á¤´¨S°_¦â¤p´²¤á¦A¨Ó¾á¤ß¤]´N¤Ó±ß¤F¡I¨ó©M³Ì«á¤@¦¸²{¼W¬O20¤¸¡A¦ý¥ý«e¤]¦³¤£¤Ö10¤¸ªº¡C
·|­û:FLYER10133103µoªí®É¶¡:2017/6/15 ¤U¤È 03:55:38²Ä499½g¦^À³
§Ú·Q¸ô¥ý¥Í³o¦¸¦^Áç·í¸³¨Æªøªº¾÷·|À³¸Ó«Ü°ª...

¥t½Ð±Ðª©¤W¦³¤H¥h°Ñ¥[ªÑªF·|©O? ¥i§_¤À¨É¤@¤U?ÁÂÁÂ!!

·|­û:¥~¦æ¤H10135615µoªí®É¶¡:2017/6/15 ¤U¤È 03:11:18²Ä498½g¦^À³
§§¤hÂ_µÃ¦X¨äºG¯P¡A¥²¤j¯u¦³¾z¤O¡F½Ð°Ý°¨¸ô¥ý¥Í·|¤£·|¦^Áç·í®a¡A³o®a¤½¥q¸ò¤H®a¤£¤@¼Ëªº´N¬O¥D¨ÆªÌ´X¥G¨S¤°»òªÑ²¼¡A«ù¦³¤@ÂIÂIªÑ¥÷«o¥i±±¨î¤@­Ó¶°¹Î¯u¦³¥»¨Æ¡C
·|­û:¥²³Ó10142431µoªí®É¶¡:2017/6/15 ¤U¤È 01:18:47²Ä497½g¦^À³
·íªì¤T¤Q¦h¤¸®É³£ÁÙ¦bÅu¥­

³Ì¦h«ùªÑ¨â¦Ê¤»¤Q±i¥ª¥k

©Ò©¯°±·l±o©y

§_«h¦A¹ï¤Á³s©R³£¨S¤F

·|­û:¾ÖÅ@ªÌ10140685µoªí®É¶¡:2017/6/15 ¤W¤È 11:46:44²Ä496½g¦^À³
³oÀɪѲ¼®t¤£¦h­n§P¦D¤F:¦º¦D

¨S±Ï,¥H«á®£³£·|²_¬°¦¹¶°¹Î¥¼¤W¥«ÂdªÑ²¼

¥X³fªº¼Ðªº¤F

·|­û:¥~¦æ¤H10135615µoªí®É¶¡:2017/6/15 ¤W¤È 11:42:53²Ä495½g¦^À³
ªÑªF·|°£¤FÅv¶Õ¤À°t¥~¥»·~¤S¬O¥Fµ½¥i³¯¶Ü¡H
·|­û:¥²³Ó10142431µoªí®É¶¡:2017/5/27 ¤U¤È 10:41:46²Ä494½g¦^À³
¸`¿ý¤µ¦~ij¨Æ¤â¥U¸ê®Æ

¤£¥Nªí¦hªÅ¥ß³õ

§Oµ¹§Ú¬ï¤p¾c

·sÃĶ}µo³¡¤À¡AºXÄ¥²£«~ FB825 ¶¶§Q¦b¬ü°ê§¹¦¨¤HÅéÁ{§É¤@´Á¸ÕÅç¡AÅã¥ÜÃÄ

ª«¦w¥þ©Ê¥BÃÒ¹êÃĪ«§@¥Î¾÷¨î¡A¸ÕÅçµ²ªG¤]®i²{ FB825 ªø®Ä©ÊªºÃĪ«Àu¶Õ¡AFB825

³q¹L TFDA ¼f¬dÀò­ã¶i¤JÁ{§É¤G´Á¸ÕÅç¶¥¬q¡C¥t¥H¡u¥þ¤HÃþ§ÜÅé®w¡v§Þ³N¦Û¦æ³Ð

·s¶}µoªº FB704A¡A¤w§¹¦¨©ñ¤j¥Í²£»sµ{¶}µo¡A¦¨¥\±N¦Û¦æ¶}µoªº¤ÀªR¤èªk¡B¾¯

«¬¡B¥H¤Î»sµ{§Þ³NÂಾ¦Ü¬ü°ê¦X§@ CMO ¼t¡A¶¶§Q§¹¦¨»s¦¨©ñ¤j¡A²{¤w¶i¤J GMP

¥Í²£»sµ{¶}µo¶¥¬q¡A¹w­p 106 ¦~¤U¥b¦~¦V¬ü°ê FDA ¥Ó½Ð·sÃÄÁ{§É³\¥i¡Cµ¦²¤§G§½

¤¤°ê¥«³õªº¥Íª«¬Û¦üÃÄ FB317¡A¤wÀò±o¤¤°ê CFDA ·sÃÄÁ{§É¸ÕÅç³\¥i¡A¶}©l°õ¦æ

Á{§É¸ÕÅç¡A¨Ã¿n·¥»P¦X§@¹Ù¦ñ¦@¦P¶}³Ð¤¤°ê¥«³õ¡CªvÀø·R´þ¯fªº¥Íª«¬Û¦üÃÄ

FB121¡A«ùÄòÀu¤Æ¥Í²£»sµ{¶}µo¡A­°§C¥Í²£¦¨¥»¡A²{¥iª½±µ¶i¦æ¥Í²£»sµ{©ñ¤j¡A

¥[³t¶}µo®Éµ{¡A¥i±æ¹Å´f§ó¦hªº·R´þ¯f±w¡C

¬ã¨sµo®i¦¨ªG»¡©ú

¥»¤½¥q¥D­nÃĪ«¶}µo­pµe¤À¶µ»¡©ú¦p¤U¡G

(1)FB825 (Anti-C£`mX)§ÜÅé·sÃÄ

FB825 ¬ãµo¦¨ªG·J¾ã¦p¤U¡G(a)¥þ²y±M§Q§G§½¡G¤w³°Äò¨ú±o¬ü°ê¡B«n«D¡B

¿D¤j§Q¨È¡B¥H¦â¦C¡B¤¤°ê¡B­»´ä¡B¿Dªù¡B¦L¥§¡B¤é¥»¡BÁú°ê¡B«Xù´µ¡B·s

¥[©Y¡B¾¥¦è­ôµ¥¦h°ê±M§Q¡A©|¦³¥]§t¼Ú¬wµ¥°ê±M§Q«ùÄò¥Ó½Ð¤¤¡A¤w³v¨B§¹

¦¨¦¹¶µÃöÁä©Ê·sÃĤ§¥þ²y±M§Q«OÅ@³Êªº«Øºc¡C(b)¾¯«¬¶}µo¡G¤w§¹¦¨ÀR¯ßª`

®g©M¥Ö¤Uª`®g¨âºØ¾¯«¬ªº¶}µo¡A±N¦³§U©ó«áÄò·sÃÄÁ{§É¸ÕÅç¥Ó½Ð»PÃĪ«À³

¥Î½d³òªºÂX®i¡C(c)¬ì±M­pµe°õ¦æ¡G¤w¨ú±o¨Ã§¹¦¨¨â´Á¸gÀÙ³¡¬ì§Þ¬ã¨sµo®i

±M®×­pµe¡A¦¨¥\¨ú±o¸gÀÙ³¡¤§¬ì±M­pµe¸É§U·s¥x¹ô 5,700 ¸U¾l¤¸¡A°õ¦æ¦¨

®Ä³Æ¨ü¸gÀÙ³¡ªÖ©w¡C(d)Á{§É¸ÕÅç°õ¦æ¡G¤w¶¶§Q§¹¦¨¬ü°ê FDA ·sÃĤ@´ÁÁ{

§É¸ÕÅç¡AÀò±o­«­nÁ{§É¼Æ¾Ú¡A¨ÃÀò TFDA ®Ö­ã¶i¤J¤HÅéÁ{§É¤G´Á¸ÕÅç¡C

FB825 §ÜÅé¬O·s¤@¥NªvÀø¹L±Ó¯e¯fªº§ÜÅé·sÃÄ¡C¬Û¸û©ó Omalizumab

¥D­n¥\¯à¬°¤¤©M¦å¤¤´åÂ÷ªº IgE¡AFB825 ¨ã¦³·s¿oÃIJz¾÷¨î¡A¥¦¯à³z¹L»¤

¾É²Ó­M­ä¤`©M§ÜÅé¨Ì¿à©Ê²Ó­M¬r±þ§@¥Îµ¥¾÷¨î§í±þªí²{½¤Æ^´O«¬ IgE ªº B

²O¤Ú²Ó­M (mIgE-B ²Ó­M)¡A±q¤W´åªýÂ_ IgE ªº¤Àªc¡A¹F¦¨¹L±Ó¯e¯fªºªvÀø

»P¹w¨¾¡C©ó¤@´ÁÁ{§É¸ÕÅ礤®i²{ÃĪ«¦w¥þ©Ê¥H¤ÎÃÒ¹êÃĪ«§@¥Î¾÷¨î¡C

¦¹¥~¡A»P¥þ²y°ß¤@®Ö­ã¥Î©ó¤¤­««×®ð³ÝªvÀøªº§ÜÅéÃĪ« Omalizumab

¬Û¤ñ¸û¡AFB825 §ÜÅé·sÃĨ㦳¥H¤U¦h¶µ¼ç¦bµo®i§Q°ò»P°Ó¤ÆÀu¶Õ¡G

A.¤¬¸É©Ê¡GÀ±¸É°ª IgE ªí²{¯f±w(>1500IU/ml)ªºªvÀø¯Ê¤f¡C

B.¿W¯S©Ê¡GÃIJz¾÷¨î¿W¯S¡B©ú½T¡C

C.¥[­¼©Ê¡G©M Omalizumab ¨Ö¥Î¡A¥i´î§CÃĪ«¥Î¶q¡A¹F¦¨³Ì¨ÎÀø®Ä¡C

D.¹w¨¾©Ê¡G¥i¥Î©ó©u¸`©Ê¹L±Ó¯e¯f¤§¹w¨¾¡C

E.¼sªx©Ê¡G¾AÀ³¯g¸û Omalizumab §ó¬°¼e¼s¡A¥i¾A¥Î©ó§ó¦hªº¹L±Ó©M®ð³Ý

±wªÌ¡C

F.ªø®Ä©Ê¡G¥Ñ¤@´Á¸ÕÅç¼Æ¾Ú±À´ú¡AFB825 ±N¥i¯à 3 ­Ó¤ëµ¹ÃĤ@¦¸¡A±N¤j´T

­°§CÂåÀø­t¾á¡A¼W¥[¨Ï¥Î¤è«K©Ê

(2)FB704A (Anti-IL6) ¥þ¤H§ÜÅé·sÃÄ

FB704A ¬O¥»¤½¥q§¹¥þ¦Û¥D¶}µoªº³æ®è§ÜÅé·sÃÄ¡A¹B¥Î¦Û«Ø¤§¡u¥þ¤H

Ãþ§ÜÅé®w¡v¡A¤w§¹¦¨§ÜÅé¿z¿ï¡B®Ä»ù´£¤É¡B³J¥Õ½è¤Î²Ó­M¼h¯Å¥\¯à©Ê©M¦w

¥þ©ÊÅçÃÒ¡B°ª²£¶q²Ó­M®è«Øºc¡B¤W¡B¤U´å»sµ{¶}µoµ¥ÃöÁä¶}µo¤u§@¡C³z¹L

³æ¾¯¶qÆFªøÃþ¬r²z¸ÕÅç¡Aªì¨BÃÒ¹êÃĪ«¦w¥þ©Ê»P¥b°I´Á¡A¬Ò³q¹LÃĪ«µo®i

ªùÂe¡A¤j´T­°§CÃĪ«¦w¥þ©ÊªººÃ¼{¡C¥»¦~«×§¹¦¨»sµ{©ñ¤j¸Õ²£¡A²£«~«~½è

¤ÀªR¡A¨Ã±Ò°Ê¦h¾¯¶qÆFªøÃþ°Êª«ÃÄ¡B¬r²z¸ÕÅç¡C±M§Q¥Ó½Ð³¡¤À¡AFB704A

¥þ¤H§ÜÅé·sÃĤw¨ú±o¥xÆW¤Î¬ü°ê±M§Q®Ö­ã¡A¥B¥Ñ PCT ­l¦ù·s¼W¤C°ê¤§¥¿¦¡

±M§Q¼f¬d¡A¨Ã±N³z¹L¾¯«¬¶}µo©M¾AÀ³¯gÂX®iµ¥¤è¦¡¡A±j¤Æ±M§Q«OÅ@½d³ò»P

©µªø±M§Q«OÅ@®É­­¡C

FB704A ¸g¥Ñ¦h¶µÂ÷Åé¡B¬¡Åé¥\¯àÅçÃÒ¸ÕÅçµ²ªGÃÒ¹ê¡AFB704A ¥Íª«¬¡

©ÊÀu©óù¤ó»sÃĤw¤W¥«¾P°â¤§ÀÀ¤H¤Æ§Ü IL6 ¨üÅ骺 Tocilizumab¡A¥]¬A¦h¶µ

§K¬Ì½Õ¸`¸ÕÅçÃÒ¹ê FB704A ¯à¦³®Ä§í¨î¤HÃþ¦h¾ã²Ó­M¤Àªc«Pµoª¢¿E¯ÀÄÀ©ñ

ªº¬¡©Ê¡Aª½±µÅçÃÒ FB704A ¨ã¦³Àu©ó Tocilizumab ªvÀøÃþ­·Àã©ÊÃö¸`ª¢¤§

¼ç¤O¡C¦b§í¨îÀù¯gªº¯e¯f¼Ò¦¡´ú¸Õ¤¤¡AÃÒ¹ê FB704A ¤£¶È¥i¦³®Ä§í¨î¦åºÞ

·s¥Í¤Î¸~½FÂಾ¡A¨Ã¤j´T´î½wÀù¯g´c¯f½è©Ò³y¦¨ªºÅé­«´î»´¡A¦P®É¦³®Ä´£

¤É¸~½F¤p¹«ªº¦s¬¡²v¡A¤S FB704A ¸g¹L¤@¨t¦C²Ó­Mµ²¦X¤ÀªR¡B²Ó­M¿E¯ÀÄÀ

©ñ¡B·»¦å´ú¸Õµ¥¦w¥þ©Ê¸ÕÅç¡AÃÒ©ú¦w¥þ©Ê·¥¨Î¡C

¤¶¥Õ¯À 6 (IL6)¬OÅ餺«D±`­«­nªº§K¬Ì½Õ±±»P²Ó­M¼W¥Í«P¶i¦]¤l¡C®Ú¾Ú

¬ì¾Ç¤åÄm³ø¾É¡A¤wª¾ IL6 »P¦h¶µ¯e¯fµo¥Í¾÷Â঳Ãö¡A¬O¥Ø«e¸ó°ê¤jÃļt¥þ

¤O¶}µo¤§ÃĪ«¼Ðªº¡CFB704A ¥Ø¼Ð±ÂÅv¤jÃļt¦@¦P¬ãµo¡A³W¹º 106 ¦~¤U¥b

¦~¦b¬ü°ê´£¥X·sÃÄÁ{§É¸ÕÅç(IND)¥Ó½Ð¡A¥[³t®Ö­ãÀ³¥Î©óÃþ­··Ã©ÊÃö¸`ª¢

ªvÀø¤§§Ü IL6 ¥þ¤H§ÜÅé·sÃÄ¡A¨Ã¿n·¥±´¯Á¨ä¥L¾AÀ³¯g¡A¼W¥[ÃĪ«¥«³õ»ù­È¡C

(3)FB121 (Ibalizumab ¥Íª«¬Û¦üÃÄ)

FB121 ¬°ªvÀø·R´þ¯f¬r(HIV)·P¬V¯gªº§ÜÅéÃĪ«¡A§@¥Î¼Ðªº¬°¤HÃþ T

²Ó­Mªí­±ªº CD4 ¤À¤l¡ACD4 ¬O·R´þ¯f¬r·P¬V¥²­nªº½¤³J¥Õ¤§¤@¡CFB121

§ÜÅéµ²¦X CD4 «á¡AªýÂ_·R´þ¯f¬r¶i¤J T ²Ó­Mªº²Ó­M¿Ä¦X§@¥Î¡AÂǦ¹¨¾¤î

·P¬V¡A¹F¦¨ªvÀø¥Øªº¡CFB121 ¬°§Ü CD4 §ÜÅéÃĪ«¡A¤£·|´î·l T ²Ó­M¦Ó¶Ë

®`¯f±w¯Ü®zªº§K¬Ì¨t²Î¡A¨ã¦³¼sªx¯f¬r§í¨î¯à¤O¡C

¥»¤½¥q¬ð¯}§Þ³NªùÂe¡AÀ³¥Î¦Û¦æ

·|­û:¤p¶Â½Þ10140151µoªí®É¶¡:2017/5/27 ¤W¤È 12:32:46²Ä493½g¦^À³
°ò¥»¤W¡A´Nºâ§A°Ý¨ì§Ö¤U¥«ªº¤½¥q¡A¥L¤]·|¦^§A¤½¥qÀç¹B¤@¤Á¥¿±`XD

Á{®ÉªÑªF·|¡A¤f¤fÁnÁn»¡´«ªÑ¤ñ¨Ò¨S°ÝÃD¡A¦ý½M¤l³£¬Ýªº¥X¨Ó°ÝÃD«Ü¤j¡Aµ²ªG¨Æ¹êÃÒ©ú¡A´«ªÑ«á±q22¶^¨ì17¤¸(¨ì¥Ø«e¬°¤î)....

§Ú«e­±¤]»¡¡A³Ì¤j°ÝÃD¬O¤½¥q¦Û¤v¤]»{¬°¥Ø«eªºÃÄ¡A¥«­Èµ¥©ó¹s(½Ð°Ñ¦Ò«e­±ºâªk)¡A¤~·|¥Î22¤¸·í§@¦Û¤vªº¥«­È

­Y¨S¦³¹Ï§Q¨ó©M¤jªÑªF¬O¨Æ¹ê¡A¨º´N¬O©Ó»{¦Û¤vªºÃĤw¸g¨S»ù­È¡A¨º¤½¥qÁÙÀç¹B¥¿±`¶ÜXDD

·|­û:andy10144449µoªí®É¶¡:2017/5/26 ¤U¤È 10:04:25²Ä492½g¦^À³
¤½¥qµo¨¥¤H»¡ ³Ìªñ±µ¨ì«Ü¦hÃö¤ß¹q¸Ü ¡A¤½¥qÀç¹B¤@¤Á¥¿±`¡A¦³°ÝÃD½Ð°Ñ¥[¤µ¦~ªÑªF·|¡AFb825¥Ø«e¥¿¦b°õ¦æTFDA Pase 2,¦Ü©ó¬ü°ê°õ¦æpase 2 «h·t¥Ü¨S¦³¥²­n
·|­û:¾ÖÅ@ªÌ10140685µoªí®É¶¡:2017/5/26 ¤W¤È 11:41:02²Ä491½g¦^À³
¤W©P«ùªÑ1000±i¥H¤Wªº¤jªÑªF,¥X²æ900±i¥H¤W

¬u²±¤w¦¨¬°¨ó©M¤jªÑªFªº´£´Ú¾÷¤F

10-15¤¸ªº¬u²±,¥¼¨Ó¤£¤[©Î³\·|¬Ý¨ì

·|­û:¤p¶Â½Þ10140151µoªí®É¶¡:2017/5/26 ¤W¤È 11:04:53²Ä490½g¦^À³
ÁÙ°O±o¥ý«e³o½g·s»D¶Ü¡H

¥x¼t°Ñ¥[¼¯®Ú¤j³q°ê»Ú¥ÍÂå¦~·|¡]J.P. Morgan Healthcare Conference¡^¶Ç¨Ó³ß°T¡A¥]¬Aù¤ó¡B¼b¥Í¡B§¨Ó¡B¿ÕµØµ¥°ê»Ú¤@½u¤j¼t¶}¥X±ø¥ó¡A±N§ÞÂà¥x¼t§ÜÅéÃIJ£«~¡A¨ä¤¤¬u²±¡B¦X¤@µ¥¤½¥qªº²£«~§Þ³N¸ß°Ý«×°ª¡A³Ì§Ö¥»©u¥i±æÃ±­q±ÂÅv¨óij¡C

¬°¦ó¿ð¿ð¨S¤U¤å¡H§Ú²q³Ì¦³¥i¯àªºµo®i¬O¡A¤¤¤Ñ­nªº±ÂÅvª÷¡A¸ò¬u²±ªº¥«­È®t¶Z¹L»·¡A¤£Ä@·N¦¨¬°©Ô©ïªÑ»ùªºª£¤â¡A©Ò¥H¡A¤@ª½¨S¦³¥æ¶°¡ã

¬JµM¤w¸g¤W¥«Äw¸ê¡Aºû«ùªÑ»ù¦X²z©Ê¥»¨Ó´N¬O¤½¥qªº¸q°È¡Aµ²ªG·d¨ì³s½Í§P³£¨ü¨ì¼vÅT¡A³o¥s°µ°½Âû¤£µÛ»k§â¦Ì¡ã

¬u²±·í®É¤W¥«»ù®æ¬O40¤¸¡A¤]´N¬O¤½¥q»{¬°¤½¥qªºÃÄ¡A»ù­È¬°15X4.0-15(²{ª÷)=45»õ¡C³Ìªñ¸ò¨ó¦X¦X¨Ö¡A22X1.5-12(²{ª÷)-21(Æp¥Û¥Í§Þ¼ç¦b»ù­È)¡×0 ¬Ý¨ì¨S¦³¡A¤½¥q»{¬°¤â¤Wªº·sÃÄ¡A²{¦b¤@ÂI»ù­È³£¨S¦³¡A§A­Ì·í¤jÃļtªº·|­p¬O¶Ì³J¶Ü¡H

­Yªñ´Á¯à½Í¨ì±ÂÅv¡A§Ú²q±ø¥ó¤@©wÄê¨ìÃø¥H·Q¹³¢æ¢Ò¡A§A­Ì´NÄ~ÄòÀ£§CªÑ»ù§a¡ã

·|­û:¤p¶Â½Þ10140151µoªí®É¶¡:2017/5/26 ¤W¤È 10:42:34²Ä489½g¦^À³
¨Ó¨ì 17Åo¡ã¥i±¤¨S¿ú¶RÅo¡ã

¦pªG¥ìÁÙ¦bªº¸Ü¡AÆp¥Û¥Í§Þ­n¤W¥«¡AªÑ»ù¤@©w­n©Ô©ï¡A§Ú²q´ú·|¥X¤¤¸Î¯E¹©¨Ó©Ô¬u²±¡A¥u¬O¦Ü¤ÖÁÙ¦³¤»­Ó¤ëªº®É¶¡¡A¦ó®É·|¶}©l¹B§@¡A´NÃøÁ¿¤F¡ã

·|­û:¥~¦æ¤H10135615µoªí®É¶¡:2017/5/24 ¤W¤È 11:16:51²Ä488½g¦^À³
¹w´ú¡A¥i¯àÁÙ¦³¤jµ§­Ó¤H­nÂà±b¡A¨S¿ìªk³o¬Oµ|¨î¤Wªº°ÝÃD¡Aµ|«Ü¤j§r¡I
·|­û:¥~¦æ¤H10135615µoªí®É¶¡:2017/5/23 ¤U¤È 10:14:33²Ä487½g¦^À³
§Ú²q¡AªÑ»ù¤U±þªº¥D¦]À³¬O¨ó©M¤jªÑªFÁ×µ|§@©Ç¡H¥¼¤W¥«Â࿳Âd­n½Ò¼x©Ò±oµ|ªº§r¡C¤]®t¤£¦h¤F¡A¦A±þ´N¨S·N¸q¤F!
·|­û:¤p¶Â½Þ10140151µoªí®É¶¡:2017/5/23 ¤U¤È 09:13:36²Ä486½g¦^À³
²{¦bªÑ»ù¤w¸g¤£¨ã·N¸q¡A·Q¶RªºÀ³¸Ó³£¶Rº¡¤F¡A¥u¯à¥ô¥Ñ¤j¤á±±¨îªÑ»ù¡A©ú¤Ñ´Nºâ±þ¨ì17¡A¤]¨SÔ£¦n·N¥~¡A¤j¤á·Q¯}©³¦¬¡A¤]¦¬¤£¨ì´X±i¡A¬Ý«e°}¤l´X¦Ê±i¡A´N©Ô¨ì10%¡A¦Ó³o¸Ì­±À³¸Ó98%³£ÁÙ¬OÂà±bªº¥æ©ö§a¡C

¸ò¥ý«e¤@¼Ë¡A¥u¯àµ¥±ÂÅv¡A©Î¬OÆp¥Û¥Í§Þ¤W¥«ªº¦n®ø®§¡A³o¬q®É¶¡¡A´NÅý¤j¤á¦Û¤vª±§a~

·|­û:¥²³Ó10142431µoªí®É¶¡:2017/5/23 ¤W¤È 11:51:44²Ä485½g¦^À³
§¯Ã~

±þ«Ü¤j

·|­û:andy10144449µoªí®É¶¡:2017/5/23 ¤W¤È 10:42:43²Ä484½g¦^À³
¯}©³ ²M­Ü¤j©ç½æ ­n¶R­n§Ö
·|­û:¥~¦æ¤H10135615µoªí®É¶¡:2017/5/22 ¤U¤È 12:05:33²Ä483½g¦^À³
®ð­Y´åµ·¡I¬Ý¦ü¯dµ¹°ß¤GÀò§Qªº­û¤u«Å¬ªºÞ¹D¡F¦]¬°³ÌÁ@¤£°_ªÑ»ùªº³£¬O¦Û¤v­û¤u¤£¬O¶Ü¡H
·|­û:ªü·ç10144461µoªí®É¶¡:2017/5/14 ¤U¤È 11:00:51²Ä482½g¦^À³
ÁÂÁ¨â¦ì¤j¤jªº¸Ñ´b!

¥t¥~FB317±q2016/6¤ë®³¨ìCFDA¤@´Áªº¥Ó½Ð& FB704A¤@ª½°±¯d¦bÁ{§É«e,¯u§Æ±æ¤µ¦~ªÑªF·|FB317 &FB704A¦³¶i¤@¨Bµo®iªº®ø®§!

·|­û:¤p¶Â½Þ10140151µoªí®É¶¡:2017/5/12 ¤U¤È 03:24:55²Ä481½g¦^À³
±i¤l¤å³Õ¤h§ÞÂàUB221?·Q¤£³q!

§ÚÅ¥¨ìªº¤K¨ö¬O¡A¥»¨Ó³o­Ó±i³Õ¤h¬O¤£¥´ºâ¶}µo¤U¥h¡A¦Ü©ó¬°¦ó¤£¶}µo¡A¬Æ¦Ü¬°¦ó²{¦b·|®³¥X¨Ó¶}µo¡A§Ú´N¤£²M·¡¤F¡]§Ú­Ó¤H¬O²q´ú¡A¢Ô¢Ð825¬OÀu©óub221¡A¤¤¶¡²£«~·íµM´N¥ý©ñ±ó¡A°£«D¢Ô¢Ð825¥¢±Ñ¡A¤~·|­«·s¦Ò¼{®³¥X¨Ó¬ãµo¡CÁp¥ÍÃĬO·s¤½¥q¡A¨S¦³FB825¡A·íµM·|·Q®³¥t¤@­Ó¨Ó¬ãµo¡A¥u­n¦¨¥\¡AÁÙ¬O·|ÁÈ¡^

¥L­Ì­n¸¹ºÙ¥|¥N¡A¤­¥N¡A¤]¤£·|¦³¤H¥X¨Ó¤Ï»é¡A²¦³ºµo©úªÌ³£¬O±i¤l¤å¡A°ò©ó§¼Æ¬u²±À³¸Ó¤]µLªk¦h»¡¨Ç¤°»ò§a¡ã

·|­û:¤p¶Â½Þ10140151µoªí®É¶¡:2017/5/12 ¤W¤È 07:08:54²Ä480½g¦^À³
®Ú¾ÚªÑªF·|ªº»¡ªk¡AUB-221¬O¤@¥Nªº¶i¶¥ª©¡A¥u¯à§í¨îIgE¥Í¦¨¤£¯àªýÂ_¡A¤]´N¬O¤£¯à®Úªv¡A©Ò¥H¡A­Y¥H¼ç¤O¨Ó¬Ý¡AÁÙ¬O¤£¦pFB825¡A¦ý¬O¡A¤@¼Ë·|·m¦P¤@¶ô¥«³õ¡C
·|­û:¥²³Ó10142431µoªí®É¶¡:2017/5/12 ¤W¤È 12:36:42²Ä479½g¦^À³
UB-221¾AÀ³¯g¬°¹L±Ó©Ê®ð³Ý¡B¹L±Ó©Ê»óª¢¡B²§¦ì©Ê¥Ö½§ª¢¡B­¹ª«¹L±Ó¡BºC©Ê¦Ûµo©ÊëC³Â¯lµ¥

¡A­n¬Ý¥¼¨Ó«ÅºÙ¾AÀ³¯g¬°¦ó¡H

FB825«ÅºÙ¾AÀ³¯g¬°²§¦ì©Ê¥Ö½§ª¢¡A¤w¦bTFDA¤G´Á¡AUB-221¤µ¦~²Ä¥|©u­n¥Ó½ÐFDA¤@´Á¡A¦³

¥i¯à¬O¦b¤£¦Pªº¶]¹DÁɶ]§a¡I

·|­û:ªü·ç10144461µoªí®É¶¡:2017/5/11 ¤U¤È 11:50:32²Ä478½g¦^À³
¬u²±FB825»Pù¤óAnti-M1³£¬O²Ä¤G¥N§Ü¹L±ÓÃÄ,ªýÂ_Igeªº¥Í¦¨,¦ý¬OµLªkª½±µ®ø°£¦å²G¤¤´åÂ÷ªºIge.Áp¥ÍÃÄUB221¬O²Ä¤T¥N§Ü¹L±ÓÃÄ,¤]¬O§ÞÂà¦Û±i¤l¤å³Õ¤h,¦ý¬OUB221¸¹ºÙ¥i¥HªýÂ_Igeªº¥Í¦¨,¤]¥i¥H®ø°£¦å²G¤¤´åÂ÷ªºIge. UB221ÁÙ¦bÁ{§É«e¬ã¨s¶¥¬q!¦ý¬O¦pªGUB221¯uªº¨º»ò±j,«hFB825¥H«áªºµo®i¤£·|¨ü­­¶Ü?¦A«h,¦pªGUB221¯uªº¨º»ò±j,¬°¦ó¬u²±·íªì¤£Ä~Äò¸ò±i¤l¤å³Õ¤h§ÞÂàUB221?·Q¤£³q!
·|­û:¤p¶Â½Þ10140151µoªí®É¶¡:2017/5/11 ¤W¤È 10:37:27²Ä477½g¦^À³
­n¬Ý¬O½Ö±µ¤â¡A­Y¥u¬O»ù­È«¬§ë¸êªÌ¡A³o­Ó¤H¬O¤£·|¥D°Ê©ÔªÑ»ùªº¡A·|µ¥ÃĪº¶iµ{¡AªÑ»ù¦ÛµM¤Wº¦¡A³oºØ¤H¤]¤£­n³æÀ£¤@¤ä¡A³oÃ䥢±Ñ¡A¨ä¥L¦³¦¨¥\¤@¤ä¡A¥LÁÙ¬OÁÈ¡C©Ò¥H´«¤â§¹«á¡A¤S¬O¤@Åy¦º¤ô¡C

­Y¬Oª£ªÑªÌ¡A´«¤â§¹«á¡A§A·|µo²{·s»D¯à¨£«×¡A¬ðµM¼W¥[¤£¤Ö¡A±µµÛªÑ»ù½wºC¤W¤É¡AµM«á¡A¤@­Ó¤j§Q¦h¡AÃz¶q¤Wº¦¡A´N±µªñ§ÀÁn¤F¡C

¬O­þºØ¡A´N¬Ý¬O½Ö±µ¨«¤F¡ã

·|­û:¥²³Ó10142431µoªí®É¶¡:2017/5/11 ¤W¤È 10:29:20²Ä476½g¦^À³
¨ó©M·sÃĦX¨Ö«áªº¬u²±¡A¤­¤ë¤T¤é¤W¿³Âd¡A

¤­¤ë¥|¤é«á¦¨¥æ¶q³vº¥©ñ¤j¡A¥Ø«eÀ³¬O¤ÏÀ³

Äw½X­±§QªÅ¡A¤£ª¾¬O§_¬°§Þ³NªÑ¥X²æ¡H¤p½Þ

¤jªº¸Ü·¥¦³¹D²z¡A¤Q¦h¤¸ªº¬u²±¡A­Y¬O¬Ý¦n

FB825ªº«e´º¡A§Q¼í¤j©ó­·ÀIªº¾÷·|¸û¤j¡C

·|­û:¤p¶Â½Þ10140151µoªí®É¶¡:2017/5/11 ¤W¤È 10:05:55²Ä475½g¦^À³
¥H¥Ø«eªÑ»ù¡A¬O¤£¥Î´Á«Ý¤Ó°ªªº±ÂÅvª÷¤F¡A¤jÃļt¬Ý§AªÑ»ù³o»ò§C¡A¤£¥i¯à«_µÛª£ªÑªº­·ÀI¸ò§Añ¬ù¡C­Y¤G´Á¼Æ¾Ú¥X¨Óº}«G¡AªÑ»ù¦ÛµM·|¥ý¤Ï¬M¡Aµ¥Ã±¬ù®ÉÃļt¬Ý§AªÑ»ù³o»ò°ª¡A¤]¤£·|¦³ª£ªÑºÃ¼{¤F¡A¦ÛµM´N´±Ã±¤j³æ¤F¡ã

©Ò¥H¡A§Ú»¡­Y§A¬Ý¦nFB825¯à¦¨¡A²{¦b»ù¦ì¤w¸g·í°µ¥L¥¢±Ñ¡A­Y¦¨¥\¡A´N·|¼Éº¦¡A¥¢±Ñ¡AÁÙ¦³¨ä¥L·sÃij»µÛ¡A¥Hªø®É¶¡¨Ó¬Ý¡A½ß¿ú¾÷·|¤p¡A¦ýÀò§Q¦³¾÷·|¦n´X­¿¡A¦³¤°»ò¤ñ³oºØ§ë¸ê¾÷·|¦n¡H

¦ý¡A°O±o­n¥Î¶¢¿ú¡A¦Ü¤Ö¦³µ¥¤T¡ã¤­¦~ªº¨M¤ß¡A·íµM¡A­Y¤¤¶¡¬ðµMµo»Ã¡A¥i¥H´N¥áµ¹¨ä¥L¤H±µ¤F¡ã

·|­û:¥²³Ó10142431µoªí®É¶¡:2017/5/11 ¤W¤È 09:57:41²Ä474½g¦^À³
¶Ì¶Ì¥h¬Û«H5»õ¬ü¤¸±ÂÅvª÷¡AµL¸Ü¥i»¡¡A

¤ßùتº·Î¼õ¡A¤ñ½ß¿ú§ó¥i©È¡A§NÀR§ä¥X

¦³§Qªºµ¦²¤§a¡I

·|­û:¤p¶Â½Þ10140151µoªí®É¶¡:2017/5/11 ¤W¤È 09:52:08²Ä473½g¦^À³
¥Ø«eªºªÑ»ù¡A°ò¥»¤W´Nºâ¢Ô¢Ð825¥¢±Ñ¡A¤]¨S¦³¶^ªºªÅ¶¡¡A¬u²±ªº·sÃĤS¤£¬O¥u¦³FB825¡A¦ýªÑ»ù«o¤Ï¬M¦¨FB825¥¢±Ñ¦¬³õ¡A³oÀ³¸Ó¬O¥Í§Þ¸Ì­±°ß¤@¤@¤ä§a¡C

®Ú¾Ú¸ê®Æ¨Ó¬Ý¡A¦X¨Ö«áÆp¥Û¥Í§Þ¾Ö¦³¬u²±40%¡A¦Ó¤¨¦Ñ¾Ö¦³Æp¥Û¥Í§Þ¡A­YÆp¥Û¦~©³­n¤W¥«¡A¬°¤F©Ô°ªµo¦æ»ù®æ¡A¬u²±ªÑ»ù·|Ãø¬Ý¶Ü¡H°£«D³o´X¤Ñ¬O¤¨¦Ñ½æ¦^µ¹¨ä¥LªÑªF¡A¨º´N¨SÔ£¦n´Á«Ý¤F¡ã

°ò¥»¤W¡A­Y¬Ý¦nFB825¡A¦³¶¢¿ú´N¥[½X¡A¥H¥Ø«eªÑ»ùº¦­Ó¤­­¿¤£¬OÃø¨Æ¡A´Nºâ¥Î®É¶¡³ø¹S¨Ó¬Ý¡A¥xªÑ¤]¨S´X°¦¥i¥H¦³³o¼ç¤O¡A­«ÂI¬O¡A§A­n¨IµÛ¦í®ð¡A§O¤¤³~³Q¬~±¼¡C

¥t¥~¡A¤]¦]¬°ªÑ»ù³Q¾Þ±±¡A­þ¤Ñ§Q¦h«e¦³¤H¤jÁ|¶R¶i¡A¨º´N¥i¥H¥hÃÒºÞ·|¥hÀËÁ|¡AªÑ»ùªø´Á±´©³¡A«ç»ò¥i¯à¬ðµM¤£­p»ù®æ¤j¶q¶R¶i¡A¤j¶q¶R¶iªÌµ´¹ï¬O¤º½u¥æ©ö¡C©Ò¥H¡A¥L­Ì­n¶R¡A¤]¥u¯à¶X§Q¦h«e¡AÀ£§CºCºC¦Y³f¡A¤½¥¬§Q¦h«á¡A¤@¤Ñº¦¨¬¡A´²¤á·Q¶R¤S±o°ª»ù¶R¤F¡ã

·|­û:¾ÖÅ@ªÌ10140685µoªí®É¶¡:2017/5/11 ¤W¤È 09:45:57²Ä472½g¦^À³
¥²³Ó¤j,¬O§Ú­Ì¤Ó¦­¶i³õ¤F

Á{§É2©Î3´Á¤~¶i³õ,¥i¥H¬Ù±¼N¦~®É¶¡¦¨¥»

¤¤¸Î ¯E¹©¤]¬O¦p¦¹

·|­û:¥²³Ó10142431µoªí®É¶¡:2017/5/11 ¤W¤È 09:32:40²Ä471½g¦^À³
¾Ö¤jªº¬Ýªk§¹¥þ¥¿½T

®É¶¡¦¨¥»À³¸Ó¤]¬O§ë¸êªº¾÷·|¦¨¥»¨ä¤¤¤@¶µ

¦³®É¶¡§Ú¦A¥J²Ó¬ã¨s¨ó©Mªº§ÜÀùÃĦ³¦ó§Q°ò

³Ìªñªº¶iµ{À³¸Ó¬O9¤ë1¤é«áFB825 2aµ²ªG

½ß¿ú¤]¥u¯à©Ç¦Û¤v¾ÇÃÀ¤£ºë¤F

·|­û:¾ÖÅ@ªÌ10140685µoªí®É¶¡:2017/5/11 ¤W¤È 09:19:59²Ä470½g¦^À³
®É¶¡¦¨¥»«Ü­«­n

¦pªGµ¥«Ýªºµ²ªG,¦³¦p¤¤¸Î,¯E¹©ªº¤@¤jªi±j涨,­È±o

¦ý¦p¬Û¤Ï,¨º......

§O§Ñ¤F,¥u­n¬O¤¤¤Ñ¶°¹ÎªºªÑ²¼,³£¤£¤j·|º¦

¦¹¤ä¬O§_·|¨Ò¥~,,,,

·|­û:¥²³Ó10142431µoªí®É¶¡:2017/5/11 ¤W¤È 08:22:44²Ä469½g¦^À³
§ë¸ê³Ì§Ò¿Ð¥X²{·P©Ê¥¢¥h²z©Ê¡A«U»y»¡¤£­n©MªÑ²¼

½ÍÅÊ·R¡A»¡ªº´N¬O³oºØ±¡§Î¡A¬Ý¿ù¤è¦V¤H¤H³£·|¡A

­«ÂI¦b©ó­×¥¿»PÀ˰Q¡A§ë¸êªº¥Øªº´N¬OÁÈ¿ú¡A§O¾E

«ã©ó©M§A«ù¬Û¤Ï¤è¦Vªº¤H¡A¦h¤Ö¸q¥¿ÃãÄYªº¨¥»y¡A

¤£¹L¦b±»¹¢¦Û¤v¬Ý¿ù¤è¦V¡AªÑ¤Í³\¦hÄ_¶Qªº¸ê°T¡A

§Ú³£¬Û·í­«µø¡A¹ï¿ù»P»ù­È§PÂ_¨ú¨M©ó¦Û¤v¡C

§Ú­n¦^À³¥»¸ÜÃD
·|­û:
§@ªÌ:
¬ÛÃöªÑ²¼¤½¥q¦WºÙ:¬u²±¥Íª«¬ì§Þ
¤º®e:
½Ð¥ýµn¤J­Y±z©|µL·|­û¨­¤À¡A½Ð¥ý¥Ó½Ð±b¸¹
°Q½×°Ï¬ÛÃö³W©w¡G
1.­Y±b¸¹¶¢¸m¹L¤[¨t²Î·|¦Û°Êµn¥X¡A«ØÄ³¦b¼g¦n¤å³¹¨Ã¥B©|¥¼µo°e¤§«e¥ý¦æ½Æ»s¡A¥H§Kµo°e¥¢±Ñ«á¾É­P¤º¤å®ø¥¢¡I
2.½Ð¤Å°Q½×ªÑ²¼¶R½æ©Î´£¤Î¦¨¥æ»ù¦ìµ¥¨Æ©y¡A¤Z¬O¯d¤U¬ÛÃö¥æ©ö°T®§¡A¥»ºô±N¦Û°Ê§R°£¡A¹HªÌ±NµLªkÄ~Äò°Ñ»P°Q½×¡I
3.ÄY¸T¯d¤UÁpµ¸¤è¦¡¡A½Ñ¦pLINE¡BFB¡BE-mail¡B¹q¸Ü..µ¥¡A©Î¥H¥ô¦ó©ú¥Ü¡B·t¥Üµ¥¤âªk¶i¦æÁpµ¸¡A¹HªÌ±NµLªkÄ~Äò°Ñ»P°Q½×¡I
4.¬°Á×§K®ö¶Oºô¸ô¸ê·½¡A½Ð¤Å±N¬Û¦P¤º®e³sÄòµo¦b¦h­Ó¤£¦P¥DÃD¤º¡A©ÎªÌ³sÄòµo°e¦h­Ó·s¥DÃD¡A­Y¦³¦¹Ãþ¬~ª©¤§¦æ¬°±NµLªkÄ~Äò°Ñ»P°Q½×¡I
5.ÄY¸T·N¹ÏÂǥΥ»ºô¥­¥x¤½µM´²¥¬¤å¦r©ó²³¡A¦Ó«üÂÖ¡B«V°d©Î¶Ç­z¨¬¥H·´·l¥L¤H¦WÅA¤§¨ÆªÌ¡A­Y¦]¦Ó¯A¤Îªk«ß°ÝÃD¡A·§»P¥»¤½¥qµLÃö¡A·q½Ð¿í¦u¡C

·q½Ð´L­«¥»ºô¤§¸gÀç²z©À¨Ã¿í¦uª©³W¡AÁÂÁ¡C

¼s§i¦X§@ ¥¼¤W¥«ÂdªÑ²¼¬d¸ß ¥¼¤W¥«ºô¯¸¾ÉÄý ¥¼¤W¥«ÂdªÑ²¼±MÃD ¿³ÂdªÑ²¼±MÃD ¥¼¤W¥«ªÑ²¼-¶°¹Î¤ÀÃþ ²§·~Âà§ë¸ê¥Í§Þ·~ ¤U³æ±Ð¾Ç
¥¼¤W¥«|¥¼¤W¥«ªÑ²¼|³Ì±M·~ªº  ¥xÆW¥¼¤W¥«ªÑ²¼  °]¸gºô¯¸-Copyright©2022¡£¥²´Iºô¡¤ §K¥I¶OªA°È±M½u:0800-035-178 ªA°È«H½c:postmaster@berich.com.tw
¥»ºô¯¸¬° ¥¼¤W¥«ÂdªÑ²¼¬d¸ß,¥¼¤W¥«ªÑ²¼§Y®É·s»D,¥¼¤W¥«¤½¥q¤½§i,¿³ÂdªÑ²¼¶R½æ,·Ç¤W¥«ªÑ²¼,¤¤ÅҪѬÛÃö¸ê°T¤À¨É¥æ¬yªÀ¸sºô¯¸,¸ê®Æ¶È¨Ñ°Ñ¦Ò,¨Ï¥ÎªÌ½Ð¦Û¦æ·r°u!
¥»ºô¯¸¤£¤¶¤J·|­û¶¡¤§¥¼¤W¥«ªÑ²¼¶R½æ,³æ¯Â´£¨Ñ¥¼¤W¥«ªÑ²¼¦æ±¡,«ùªÑÂàÅý,¥¼¤W¥«ªÑ²¼¹L¤á¿Ô¸ß¶È´£¨Ñ¥¼¤W¥«ªÑ²¼¥æ©ö¥­¥xµ¹·|­û¨Ï¥Î,¨Ì¥»¸ê®Æ¥æ©ö«á¬ÕÁ«¦Û­t!